Glenmark Pharmaceuticals · NSE: GLENMARK · BSE: 532296
Q3 FY21 results · Oct–Dec 2020
Glenmark Pharmaceuticals reported revenue from operations of ₹2,786.76 crore (up 1.9% from Q3 FY20) and net profit of ₹248.18 crore (up 30.0% from Q3 FY20) for Q3 FY21 (Oct–Dec 2020), on a consolidated basis.
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,786.76 | 2,735.56 | +1.9% | 2,952.48 | −5.6% |
| Other income | 15.09 | 32.96 | −54.2% | (31.88) | Turned profit |
| Total income | 2,801.85 | 2,768.52 | +1.2% | 2,920.60 | −4.1% |
| Profit before tax | 347.97 | 270.98 | +28.4% | 339.38 | +2.5% |
| Net profit for the period | 248.18 | 190.84 | +30.0% | 233.99 | +6.1% |
| EPS, basic (₹) | 8.80 | 13.52 | not comparable | 8.29 | +6.2% |
| Net margin (%) | 8.9 | 7.0 | 7.9 |
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,972.48 | 1,816.29 | +8.6% | 2,062.16 | −4.3% |
| Other income | 81.13 | 94.49 | −14.1% | 63.40 | +28.0% |
| Total income | 2,053.61 | 1,910.78 | +7.5% | 2,125.57 | −3.4% |
| Profit before tax | 533.01 | 410.64 | +29.8% | 461.55 | +15.5% |
| Net profit for the period | 442.32 | 345.53 | +28.0% | 402.88 | +9.8% |
| EPS, basic (₹) | 15.68 | 24.50 | not comparable | 14.28 | +9.8% |
| Net margin (%) | 22.4 | 19.0 | 19.5 |
Consolidated
- Filed with BSE
- 13 Feb 2021, 16:32 IST
- Board meeting
- 12 Feb 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Feb 2021, 16:32 IST
- Board meeting
- 12 Feb 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE